Toggle menu

REACT Study

Start date:
Nov 2019
End date:
Dec 2019
Co-ordinated by:
Lumira Dx
Main trial site:
RIE, Edinburgh

A performance evaluation study designed to assess the precision and accuracy of the Lumira DX point of care (POC) and C-Reactive (CRP) assay as an aid in the detection and evaluation of infection, tissue injury and inflammatory disorders.

 

In the emergency department (ED), CRP is tested in patients presenting with a variety of symptoms as an aid the detection and evaluation of infection, tissue injury or inflammatory disorders.

 

 

Primary objective  – To determine the performance of the LumiraDx POC CRP assay when compared to the Siemens Dimension reference method in patients with symptoms of infection, tissue injury and inflammatory disorders.

 

Sample size –  50 participants over a duration of approximately 4 weeks.

 

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Julia Grahamslaw

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.

Read more

INFERENCE

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)